Ultragenyx Pharmaceutical annual revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ultragenyx Pharmaceutical Revenue Growth & History (RARE)
Ultragenyx Pharmaceutical reported $673.0M in revenue for fiscal 2025, an increase of 20.18% from the previous fiscal year.
View full Ultragenyx Pharmaceutical company overviewUltragenyx Pharmaceutical annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $673.0M | $113.0M | +20.18% |
| 2024 | 2024-12-31 | $560.0M | $126.0M | +29.03% |
| 2023 | 2023-12-31 | $434.0M | $70.7M | +19.45% |
| 2022 | 2022-12-31 | $363.3M | $11.9M | +3.39% |
| 2021 | 2021-12-31 | $351.4M | $80.4M | +29.66% |
| 2020 | 2020-12-31 | $271.0M | $167.3M | +161.32% |
| 2019 | 2019-12-31 | $103.7M | $52.2M | +101.41% |
| 2018 | 2018-12-31 | $51.5M | $48.9M | +1871.48% |
| 2017 | 2017-12-31 | $2.6M | $2.5M | +1863.91% |
| 2016 | 2016-12-31 | $133,000 | — | — |
Ultragenyx Pharmaceutical quarterly revenue
Q2.16
Q3.16
Q4.16
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $214.0M | $47.0M | +28.14% |
| Q1 2026 | 2026-03-31 | $136.0M | −$3.0M | −2.16% |
| Q4 2025 | 2025-12-31 | $207.1M | $42.4M | +25.76% |
| Q3 2025 | 2025-09-30 | $159.9M | $20.4M | +14.65% |
| Q2 2025 | 2025-06-30 | $167.0M | $20.0M | +13.59% |
| Q1 2025 | 2025-03-31 | $139.0M | $30.2M | +27.72% |
| Q4 2024 | 2024-12-31 | $164.6M | $37.5M | +29.50% |
| Q3 2024 | 2024-09-30 | $139.5M | $41.4M | +42.27% |
| Q2 2024 | 2024-06-30 | $147.0M | $38.7M | +35.75% |
| Q1 2024 | 2024-03-31 | $108.8M | $8.3M | +8.30% |
| Q4 2023 | 2023-12-31 | $127.1M | $23.8M | +23.02% |
| Q3 2023 | 2023-09-30 | $98.1M | $7.3M | +8.10% |
| Q2 2023 | 2023-06-30 | $108.3M | $19.0M | +21.23% |
| Q1 2023 | 2023-03-31 | $100.5M | $20.6M | +25.72% |
| Q4 2022 | 2022-12-31 | $103.3M | $20.0M | +23.93% |
| Q3 2022 | 2022-09-30 | $90.7M | $9.1M | +11.09% |
| Q2 2022 | 2022-06-30 | $89.3M | $2.4M | +2.72% |
| Q1 2022 | 2022-03-31 | $79.9M | −$19.5M | −19.58% |
| Q4 2021 | 2021-12-31 | $83.4M | −$8.2M | −8.91% |
| Q3 2021 | 2021-09-30 | $81.6M | $177,000 | +0.22% |
| Q2 2021 | 2021-06-30 | $87.0M | $25.3M | +40.94% |
| Q1 2021 | 2021-03-31 | $99.4M | $63.1M | +173.75% |
| Q4 2020 | 2020-12-31 | $91.5M | $55.9M | +157.19% |
| Q3 2020 | 2020-09-30 | $81.5M | $55.7M | +215.78% |
| Q2 2020 | 2020-06-30 | $61.7M | $37.6M | +155.53% |
| Q1 2020 | 2020-03-31 | $36.3M | $18.1M | +99.81% |
| Q4 2019 | 2019-12-31 | $35.6M | $19.3M | +118.89% |
| Q3 2019 | 2019-09-30 | $25.8M | $14.0M | +119.33% |
| Q2 2019 | 2019-06-30 | $24.1M | $11.4M | +88.75% |
| Q1 2019 | 2019-03-31 | $18.2M | $7.5M | +70.20% |
| Q4 2018 | 2018-12-31 | $16.3M | $13.8M | +573.61% |
| Q3 2018 | 2018-09-30 | $11.8M | $11.6M | +5840.91% |
| Q2 2018 | 2018-06-30 | $12.8M | — | — |
| Q1 2018 | 2018-03-31 | $10.7M | — | — |
| Q4 2017 | 2017-12-31 | $2.4M | $2.4M | +48180.00% |
| Q3 2017 | 2017-09-30 | $198,000 | $87,000 | +78.38% |
| Q4 2016 | 2016-12-31 | $5,000 | — | — |
| Q3 2016 | 2016-09-30 | $111,000 | — | — |
| Q2 2016 | 2016-06-30 | $17,000 | — | — |
Ultragenyx Pharmaceutical revenue growth trends
Over the last five reported fiscal years, revenue grew from $271.0M to $673.0M, a compound annual growth rate of 19.95%. Ultragenyx Pharmaceutical's latest reported quarter, Q2 2026, generated $214.0M in revenue, an increase of 28.14% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Ultragenyx Pharmaceutical source filings ↗Community posts
Ultragenyx wins FDA approval for its Sanfilippo gene therapy
Ultragenyx ($RARE) received standard FDA approval for FAYUVI, the first approved treatment for Sanfilippo syndrome Type A. The single-infusion gene therapy treats neurological manifestations in pediatric patients with preserved neurodevelop ...
